Roundview Capital’s Madrigal Pharmaceuticals MDGL Stock Holding History

Roundview Capital’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-603	Closed	-$5K	–	188
2016 Q2	$5K	Hold	603	–	–	﹤0.01%	172
2016 Q1	$5K	Hold	603	–	–	﹤0.01%	174
2015 Q4	$7K	Hold	603	–	–	﹤0.01%	162
2015 Q3	$37K	Sell	603 -228	-27%	-$16.5K	0.02%	155
2015 Q2	$65K	Sell	831 -343	-29%	-$28.8K	0.02%	153
2015 Q1	$80K	Buy	1,174 +571	+95%	+$49K	0.03%	148
2014 Q4	$56K	Hold	603	–	–	0.02%	146
2014 Q3	$64K	Hold	603	–	–	0.03%	126
2014 Q2	$86K	Hold	603	–	–	0.03%	148
2014 Q1	$91K	Hold	603	–	–	0.04%	124
2013 Q4	$111K	Hold	603	–	–	0.05%	127
2013 Q3	$133K	Hold	603	–	–	0.07%	118
2013 Q2	$105K	Buy	+603	New	+$157K	0.07%	107

Other funds holding MDGL

Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Roundview Capital's MDGL Position: Q3 2016 in Review

Roundview Capital sold out of Madrigal Pharmaceuticals (MDGL) in Q3 2016, closing a stake of 603 shares — an estimated $5K sold.

Roundview Capital first reported a position in MDGL in Q2 2013 and held it in 13 quarters. The position peaked at $133K in Q3 2013. 31 funds tracked by Wall St. Rank hold MDGL as of Q3 2016.

Roundview Capital reported no remaining Madrigal Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Roundview Capital sold 603 Madrigal Pharmaceuticals shares in Q3 2016, an estimated $5K.
Roundview Capital first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 13 quarters.
Roundview Capital's Madrigal Pharmaceuticals position peaked at $133K in Q3 2013.
31 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2016.

Based on Roundview Capital's 13F filing for Q3 2016, filed 14 Nov 2016.